This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...
Clinical Trials Arena on MSN
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
(RTTNews) - Eli Lilly and Company (LLY) on Monday said its new formulation of Taltz (ixekizumab), which was approved by the FDA in May this year, is being made available across the U.S. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback